Bristol-Myers Squibb Company - Facts About STD's

Bristol-Myers Squibb(BMS) and the National AIDS Fund launched the 3rd annual " Bristol-Myers Squibb is a major pharmaceutical company whose mission statement includes: Bristol-Myers Squibb developed, manufactures, and sells several life-saving antiretroviral medications to treat HIV and AIDS: The National AIDS Fund ...

NEW YORK (Reuters) - Board members of an international group that helps ensure patient get access to HIV drugs has warned that Bristol-Myers Squibb Co's plans to close a factory in France could leave thousands of babies without a life-saving treatment for ...

Experts ask Bristol-Myers not to shut factory making AIDS drugs, thousands of kids could dieOfficials urged Bristol-Myers Squibb not to shut down a plant in France which makes AIDS drugs, saying the move will jeopardize the lives of thousands of babies.In a ...

Long-term cohorts evaluated for liver histology, including fibrosis, and viral load reduction. Patients followed in this cohort received BARACLUDE for a median of six years across the studies (ETV-022, -027 and -901) and had evaluable baseline and long-term liver biopsies. Improvement in ...

Bristol-Myers Squibb Company announced today that the U.S. Food & Drug Administration (FDA) approved the use of Reyataz (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-naive) HIV-1 infected patients. This use ...

BMY) announced today that the U.S. Food & Drug Administration (FDA) approved the use of REYATAZ (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-naive) HIV-1 infected patients. This use of once-daily ...

CASTLE gender subanalysis provides largest scale information to date about boosted protease inhibitor-based combination HIV therapy in treatment-naive women. BMY) today announced results from a pre-specified subanalysis of the CASTLE study, in which once-daily boosted REYATAZ(R) (atazanavir sulfate) (REYATAZ 300 mg taken ...

FDA officials Wednesday announced approval of a new three-drug combination pill that could mean a single pill a day for many HIV/AIDS patients.. Andrew von Eschenbach, MD, acting commissioner of the FDA, called the drug's introduction a "landmark" in the treatment of ...

Topic: Bristol-Myers Squibb Company

AIDS Awareness: Bristol-Myers Squibb 'Light to Unite Program'

Group urges Bristol to protect HIV-drug for babies

Experts ask Bristol-Myers not to shut French plant

New Data Suggest Long-Term Treatment with Baraclude (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B

U.S. Food & Drug Administration Approved the use of Reyataz (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients

U.S. Food & Drug Administration Approved the use of REYATAZ (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients

CASTLE Data Showed Boosted Reyataz (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender

First One-Pill-a-Day Drug for AIDS

Photo Gallery

From Around the Web

Video Gallery

Follow this Topic with...